How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    a. Has all of the relevant evidence been taken into account?

  • Question on Consultation

    b. Are the summaries of safety and efficacy reasonable interpretations of the evidence?

  • Question on Consultation

    c. Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    d. Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Guidance assessment consultation document for HTG10870 Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

Guidance assessment consultation document for HTG10870 Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

Cancer can start in the liver (primary) or spread to it from another part of the body (metastatic). In this procedure, a very high dose of anticancer medicine (chemosaturation) called melphalan is put into the liver. Because melphalan can be toxic to the rest of the body it is added directly to the blood supply going into the liver (percutaneous hepatic artery perfusion). Blood leaving the liver is diverted (hepatic vein isolation) and taken out of the body. It is filtered to remove any melphalan and returned to the body. The aim is to destroy the cancer without causing side effects in the rest of the body.

NICE interventional procedures guidance applies to the NHS in England, Wales and Northern Ireland.